Advanced search
Publication Cover
Therapeutics and Clinical Risk Management Volume 15, 2019 - Issue
Submit an article Journal homepage
167
Views
7
CrossRef citations to date
0
Altmetric
Case Report

Pharmacokinetic/pharmacodynamic study of posaconazole delayed-release tablet in a patient with coexisting invasive aspergillosis and mucormycosis

Pannee Leelawattanachai1 Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand;2 Department of Pharmacy, Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand
,
Preecha Montakantikul1 Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
,
Wichit Nosoongnoen1 Division of Clinical Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
&
Methee Chayakulkeeree3 Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandCorrespondence[email protected]
Pages 589-595 | Published online: 24 Apr 2019

Citations (7)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Jessica Bui, Rochelle Gellatly, Jad Othman & Julian Lindsay. (2022) Subtherapeutic concentrations of posaconazole tablet: determining risk factors and effectiveness of a standardized dose adjustment in hematology inpatients. Leukemia & Lymphoma 63:14, pages 3418-3425.
Read now

Articles from other publishers (6)

Sakineh Dadashpour, Elham Ghobadi & Saeed Emami. (2022) Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs. Medicinal Chemistry Research 31:6, pages 833-850.
Crossref
Yasmine Benhadid-Brahmi, Samia Hamane, Benjamin Soyer, Alexandre Mebazaa, Alexandre Alanio, Benjamin Chousterman, Stéphane Bretagne & Sarah Dellière. (2022) COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review. Journal of Medical Mycology 32:1, pages 101231.
Crossref
Maggie M. Chau, Kathryn Daveson, Jan‐Willem C. Alffenaar, Amanda Gwee, Su Ann Ho, Deborah J. E. Marriott, Jason A. Trubiano, Jessie Zhao, Jason A. Roberts, Monica A. Slavin, Karin A. Thursky, Jason A. Roberts, Leon J. Worth, Christina C. Chang, Sharon C‐A Chen, C. Orla Morrissey, Christopher C. Blyth & Anna Khanina. (2021) Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy and haemopoietic stem cell transplant recipients, 2021. Internal Medicine Journal 51:S7, pages 37-66.
Crossref
Beatrice Mercorelli, Anna Luganini, Marta Celegato, Giorgio Palù, Giorgio Gribaudo, Galina I. Lepesheva & Arianna Loregian. (2020) The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication. Antimicrobial Agents and Chemotherapy 64:10.
Crossref
Victoria M. Stevens, Scott W. Mueller, Paul M. Reynolds, Robert MacLaren & Tyree H. Kiser. (2020) Extrapolating Antifungal Animal Data to Humans—Is It Reliable?. Current Fungal Infection Reports 14:1, pages 50-62.
Crossref
. (2019) Amphotericin-B liposomal/posaconazole. Reactions Weekly 1772:1, pages 32-32.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.